Why the study?
LVAD support often improves cardiac histology and function in heart failure, but the cellular programs underlying this recovery remain unclear.
Does left ventricular assist device (LVAD) support and heart failure recovery induce mesenchymal-to-endothelial transition to reduce myocardial fibrosis and increase microvascular density in human end-stage heart failure and murine heart failure models?
Observational (n=24)
Single-blind (investigator blinded to sample source for histology and echocardiography)
No
Does left ventricular assist device (LVAD) support and heart failure recovery induce mesenchymal-to-endothelial transition to reduce myocardial fibrosis and increase microvascular density in human end-stage heart failure and murine heart failure models?
No takes yet. Share an insight, caveat, or question.
Heart failure recovery following LVAD support involves reduced myocardial fibrosis and enhanced microvascularization driven in part by a c-Myc-regulated fibroblast-to-endothelial cell fate transition, offering a novel mechanistic target for cardiac regeneration.
BACKGROUND: Heart failure (HF) is a significant global health problem. Left ventricular assist device (LVAD) implantation serves as a bridge for patients awaiting heart transplantation. Intriguingly, LVAD support often improves cardiac histology and function, sometimes enough to avoid transplantation after LVAD removal. However, the cellular programs underlying this recovery remain unclear. METHODS: Myocardial tissues were obtained from patients with HF at the time of LVAD implantation (pre LVAD) and explantation (post LVAD) for histological analysis and single-nucleus RNA sequencing. A murine model of HF recovery, combined with lineage tracing studies, was employed to define cellular sources of vascular repair. Cardiac function, fibrosis, and vascular density were assessed using echocardiography, histology, and fluorescent microsphere perfusion. A patient-derived cardiac nonmyocyte culture system was established to interrogate mechanisms of cell fate regulation. RESULTS: Post-LVAD myocardial tissues exhibited reduced fibrosis and increased capillary density compared with pre-LVAD samples. Across samples, fibroblast abundance was inversely correlated with endothelial cell abundance, consistent with enhanced angiogenesis during recovery. Single-nucleus RNA sequencing identified a fibroblast subset predisposed to undergo mesenchymal-to-endothelial transition, acquiring an endothelial cell identity. Additionally, nonmyocytes from pre-LVAD hearts proliferated poorly and failed to form vascular structures, whereas nonmyocytes from post-LVAD hearts displayed greater proliferation and angiogenesis capacity, forming vessel-like structures, reinforcing the association of HF recovery with angiogenic reprogramming. Mechanistically, knockdown of c-Myc by siRNA shifted post-LVAD nonmyocytes to a pre-LVAD–like state, while c-Myc overexpression by mRNA in pre-LVAD cells induced a post-LVAD–like phenotype, implicating c-Myc as 1 contributor to this fate switch. A model of HF recovery in mice mimicked the histological and functional changes in patients, with physiological evidence of increased microvascular perfusion, associated with a fibroblast-to-endothelial transition, documented by lineage tracing. CONCLUSIONS: HF recovery involves reduced fibrosis and enhanced microvascularization, partly driven by fibroblast-to-endothelial cell fate transition. c-Myc functions as 1 regulator of this transition, offering a mechanistic entry point to develop regenerative therapies in HF.
Li et al. (2026) conducted an observational in End-stage heart failure undergoing left ventricular assist device (LVAD) support (n=24). Left ventricular assist device (LVAD) support (post-LVAD state) vs. Pre-LVAD state (at the time of LVAD implantation) was evaluated on Myocardial fibrosis (% stained area) (p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: